Testimony Opposing SB 2402: Texas Pharmaceutical Initiative
TAHP member plans are concerned that SB 2402 could create a carve-out of the prescription drug program from Medicaid managed care, returning Medicaid to a fragmented fee-for-service program. If this is not the intent, we respectfully request clarifying language be added to the legislation.
Multiple studies have shown that carving drugs out of managed care in Texas would cost Texas taxpayers hundreds of millions of dollars. Equally important, we are concerned that a carve-out would negatively impact health care outcomes by creating barriers that prevent Texas families from receiving the care coordination they need to stay in their communities and lead active lives.
View the full letter.